hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer
- 18 March 2020
- journal article
- research article
- Published by Elsevier BV in Cancer Letters
- Vol. 479, 112-122
- https://doi.org/10.1016/j.canlet.2020.03.015
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81801728, 81871378)
- Shanghai Municipal Key Clinical Specialty, China (shslczdzk03403)
- Guang Ci Outstanding Youth Training Programme B (GCQN-2017-B18)
This publication has 47 references indexed in Scilit:
- Mini-review on Glycolysis and CancerJournal of Cancer Education, 2013
- Targeting cellular metabolism to improve cancer therapeuticsCell Death & Disease, 2013
- Molecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy ResistanceClinical Cancer Research, 2012
- Cancer incidence and mortality in China, 2007Chinese Journal of Cancer Research, 2012
- Mechanisms of glucose uptake in intestinal cell lines: Role of GLUT2Surgery, 2012
- Expression of human equilibrative nucleoside transporter 1 in mouse neurons regulates adenosine levels in physiological and hypoxic‐ischemic conditionsJournal of Neurochemistry, 2011
- Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd)Cancer Science, 2011
- Understanding the Warburg Effect: The Metabolic Requirements of Cell ProliferationScience, 2009
- High glucose suppresses expression of equilibrative nucleoside transporter 1 (ENT1) in rat cardiac fibroblasts through a mechanism dependent on PKC‐ζ and MAP kinasesJournal of Cellular Physiology, 2007
- On the Origin of Cancer CellsScience, 1956